Regeneron Pharmaceuticals (REGN) ROE - Return on Equity
Current and historical Return on Equity (ROE) values for Regeneron Pharmaceuticals (REGN) over the last 10 years.
|Medical||Medical - Biomedical and Genetics||$35.955B||$5.872B|
|Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma and has preclinical programs in other diseases and disorders.|